Vaxelis®

Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine

Electronic Health Record (EHR) Considerations

To begin administering VAXELIS, ensure that the product is available in the electronic health record (EHR) system.

It can take time for new vaccines to appear in EHR product lists. If VAXELIS is not yet available in the EHR, you or your staff can add it manually. This will allow for a timelier transition to VAXELIS while maintaining accuracy in patient records.

To learn how to manually add VAXELIS to your EHR system, refer to your internal or external EHR support resources.

Keep in mind that EHR security privileges tend to vary depending on practice size. The below list may help you determine who, among your staff, is most likely able to manually add VAXELIS:

- Small practice — the physician or practice administrator
- Mid-sized practice — system administrator, nurse, or any EHR super user
- Large practice — an IT staff member, clinical manager, or system administrator



VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to *Haemophilus influenzae* type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

- Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
- Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
- Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
- Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
- If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant's medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
- Vaccination with VAXELIS may not protect all individuals.
- The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

MERCK sanofi